NASDAQ: PMCB - PharmaCyte Biotech, Inc.

Yield per half year: -25.29%
Dividend yield: 0.00%
Sector: Healthcare

Share chart PharmaCyte Biotech, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.

more details
The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2010-09-17
ISIN US71715X2036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://pharmacyte.com
Цена ао 1.49
Change price per day: 0% (1.27)
Change price per week: +5.39% (1.205)
Change price per month: -19.62% (1.58)
Change price per 3 month: -15.33% (1.5)
Change price per half year: -25.29% (1.7)
Change price per year: -40.09% (2.12)
Change price per 3 year: -43.05% (2.23)
Change price per 5 year: +3 635.29% (0.034)
Change price per year to date: -22.56% (1.64)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.514 10
P/E 60.86 1
EV/EBITDA -89.49 0
Total: 3.63

Efficiency

Title Value Grade
ROA, % 0.5012 1
ROE, % 0.5949 1
Total: 0.3333

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.0212

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -98.14 0
Yield Ebitda, % -108.78 0
Yield EPS, % -1344.13 0
Total: 0
More

Institutions Volume Share, %
K2 Principal Fund, L.P. 304613 0.01
Geode Capital Management, LLC 215637 0.01
Vanguard Group Inc 171335 0.01
Equitec Proprietary Markets LLC 82727 0
Sabby Management, LLC 82373 0
Renaissance Technologies, LLC 38100 0
Dimensional Fund Advisors LP 29307 0
Blackrock Inc. 28769 0
Citadel Advisors Llc 28618 0
Schonfeld Strategic Advisors LLC 23200 0



Head Job title Payment Year of birth
Mr. Joshua N. Silverman Interim CEO, Interim President & Interim Chairman 197.92k 1970 (55 years)
Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer 380k 1958 (67 years)
Dr. Jose L. Iglesias M.D. Consulting Chief Medical Officer N/A 1957 (68 years)
Dr. Hans-Peter Hammes Member of Medical & Scientific Advisory Board and Consultant N/A

Address: United States, Las Vegas. NV, 3960 Howard Hughes Parkway - open in Google maps, open in Yandex maps
Website: https://pharmacyte.com